Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 4/20 | 0.45 |
| ▸ | CTSL | P07711 | 2/20 | 0.44 |
| ▸ | CPB1 | P15086 | 2/20 | 0.44 |
| ▸ | CTSB | P07858 | 1/20 | 0.44 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | DPP4 | P27487 | 3/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.42 |
| ▸ | DPP7 | Q9UHL4 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | CTSS | P25774 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2941384 | 1.00 | CTSK (0.45) | CTSKCTSLCPB1CTSBHSD11B1 | |
| SCHEMBL2853435 | 0.81 | CTSK (0.48) | CTSKCTSLCPB1CTSBHSD11B1 | |
| SCHEMBL2853434 | 0.81 | CTSK (0.48) | CTSKCTSLCPB1CTSBHSD11B1 | |
| SCHEMBL4263739 | 0.81 | PDE4B (0.49) | CTSKCTSLCPB1CTSBHSD11B1 | |
| SCHEMBL210039 | 0.81 | PDE4B (0.49) | CTSKCTSLCPB1CTSBHSD11B1 | |
| SCHEMBL4268253 | 0.81 | PDE4B (0.49) | CTSKCTSLCPB1CTSBHSD11B1 | |
| SCHEMBL2855357 | 0.80 | JAK2 (0.51) | CTSKCTSLCPB1CTSBHSD11B1 | |
| SCHEMBL2855355 | 0.80 | JAK2 (0.51) | CTSKCTSLCPB1CTSBHSD11B1 | |
| SCHEMBL1503863 | 0.80 | CTSK (0.50) | CTSKCTSLCPB1CTSBHSD11B1 | |
| SCHEMBL1504080 | 0.80 | CTSK (0.50) | CTSKCTSLCPB1CTSBHSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100093785-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2010-04-15 | — | — | US | disclosed |
| US-20050119486-A1 | Diamine derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2005-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093785-A1 | DIAMINE DERIVATIVES | C9, C1S, C1R | CTSK 4333/4885CTSL 2909/4885CPB1 3417/4885 |
| US-20050119486-A1 | Diamine derivatives | C9, C1S, C1R | CTSK 4247/4885CTSL 2437/4885CPB1 3108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.